AR090496A1 - Derivados biciclicos de pirazinona - Google Patents
Derivados biciclicos de pirazinonaInfo
- Publication number
- AR090496A1 AR090496A1 ARP130100972A ARP130100972A AR090496A1 AR 090496 A1 AR090496 A1 AR 090496A1 AR P130100972 A ARP130100972 A AR P130100972A AR P130100972 A ARP130100972 A AR P130100972A AR 090496 A1 AR090496 A1 AR 090496A1
- Authority
- AR
- Argentina
- Prior art keywords
- denotes
- hal
- mono
- par2
- coa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de la fórmula (1) en donde R¹ denota H, F, Cl, CN, CH₃, CH₂OH, CH₂CI, CH₂Br, CF₃, CHF₂ o CH₂F; R² denota H o A; R³ denota H, F, Cl, CH₃, CF₃ o CHF₂; X denota CR³ o N; Y denota Ar¹, Carb, Het¹ o Cyc; Ar¹ denota fenilo o naftilo que no está sustituido o que está mono-, di- o trisustituido con Hal, A, [C(R²)₂]ₚOR², [C(R²)₂]ₚN(R²)₂, [C(R²)₂]ₚHet², NO₂, CN, [C(R²)₂]ₚCOOR², [C(R²)₂]ₚCON(R²)₂, NR²COA, NR²SO₂A, [C(R²)₂]ₚSO₂N(R²)₂, S(O)ₙA, COHet³, O[C(R²)₂]ₘN(R²)₂, O[C(R²)₂]ₚAr², O[C(R²)₂]ₚHet², NHCOOA, NHCON(R²)₂, Cyc, CHO y/o COA; Ar² denota fenilo, no está sustituido o que está mono- o disustituido con Hal, A, [C(R²)₂]ₚOR², [C(R²)₂]ₚN(R²)₂, [C(R²)₂]ₚHet³, NO₂, CN, [C(R²)₂]ₚCOOR, [C(R²)₂]ₚN(R²)₂, N(R²)₂COA, NR²SO₂A, [C(R²)₂]ₚSO₂N(R²)₂, S(O)ₙA, COHet³, O[C(R²)₂]ₘN(R²)₂, O[C(R²)₂]ₚHet³, NHCOOA, NHCON(R²)₂, CHO y/o COA; Het¹ denota pirrolidinilo, azetidinilo, tetrahidroimidazolilo, tetrahidrofuranilo, tetrahidropirazolilo, tetrahidropiranilo, piperidinilo, morfolinilo, hexahidropiridazinilo, hexahidropirimidinilo, [1,3]dioxolanilo, piperazinilo, furilo, tienilo, pirrolilo, imidazolilo, pirazolilo, oxazolilo, isoxazolilo, oxadiazolilo, tiazolilo, triazolilo, tetrazolilo, piridilo, pirimidilo, piridazinilo, indolilo, isoindolilo, bencimidazolilo, indazolilo, quinolilo, 1,3-benzodioxolilo, benzotiofenilo, benzofuranilo, imidazopiridilo o furo[3,2-b]piridilo, cada uno de los cuales no está sustituido o está mono- o disustituido con Hal, A, [C(R²)₂]ₚOR², [C(R²)₂]ₚN(R²)₂, [C(R²)₂]ₚHet², [C(R²)₂]ₚAr², NO₂, CN, [C(R²)₂]ₚCOOR², [C(R²)₂]ₚCON(R²)₂, NR²COA, NR²SO₂A, [C(R²)₂]ₚSO₂N(R²)₂, S(O)ₙA, COHet³, O[C(R²)₂]ₘN(R²)₂, O[C(R²)₂]ₚAr², O[C(R²)₂]ₚHet², NHCOOA, NHCON(R²)₂, CHO, COA, =S, =NR y/u =O; Carb denota indanilo o tetrahidronaftilo, cada uno de los cuales puede no estar sustituido o puede estar mono-, di-, tri- o tetrasustituido con A; Cyc denota alquilo cíclico con 3, 4, 5, 6 ó 7 átomos de C, que puede no estar sustituido o que puede estar monosustituido con A, OH, Hal, CN o Ar² o Het²; Het² denota pirrolidinilo, azetidinilo, tetrahidroimidazolilo, tetrahidrofuranilo, tetrahidropirazolilo, tetrahidropiranilo, piperidinilo, morfolinilo, hexahidropiridazinilo, hexahidropirimidinilo, [1,3]dioxolanilo, piperazinilo, furilo, tienilo, pirrolilo, imidazolilo, pirazolilo, oxazolilo, isoxazolilo, oxadiazolilo, tiazolilo, triazolilo, tetrazolilo, piridilo, pirimidilo, piridazinilo, indolilo, isoindolilo, bencimidazolilo, indazolilo, quinolilo, 1,3-benzodioxolilo, benzotiofenilo, benzofuranilo, imidazopiridilo o furo[3,2-b]piridilo, cada uno de los cuales no está sustituido o está mono- o disustituido con Hal, A, [C(R²)₂]ₚOR², [C(R²)₂]ₚN(R²)₂, [C(R²)₂]ₚHet³, [C(R²)₂]ₚOHet³, [C(R²)₂]ₚAr², NO₂, CN, [C(R²)₂]ₚCOOR², [C(R²)₂]ₚCON(R²)₂, NR²COA, NR²SO₂A, [C(R²)₂]ₚSO₂N(R²)₂, S(O)ₙA, COHet³, O[C(R²)₂]ₘN(R²)₂, O[C(R²)₂]ₚAr², O[C(R²)₂]ₚHet³, NHCOOA, NHCON(R²)₂, CHO, COA, =S, =NR y/u =O; Het³ denota dihidropirrolilo, pirrolidinilo, azetidinilo, oxetanilo, tetrahidroimidazolilo, dihidropirazolilo, tetrahidropirazolilo, tetrahidrofuranilo, dihidropiridilo, tetrahidropiridilo, piperidinilo, morfolinilo, hexahidropiridazinilo, hexahidropirimidinilo, [1,3]dioxolanilo, tetrahidropiranilo o piperazinilo, cada uno de los cuales no está sustituido o está mono- o disustituido con Hal, CN, OR², COOR², CON(R²)₂, S(O)ₙA, S(O)ₙAr, COA, A y/u =O; A denota alquilo no ramificado o ramificado C₁₋₁₀, en donde dos grupos CH y/o CH₂ adyacentes pueden formar un enlace doble y en donde uno o dos grupos CH y/o CH₂ no adyacentes pueden estar reemplazados por átomos de N, O y/o S y en donde 1 - 7 átomos de H pueden estar reemplazados por F o Cl; Hal denota F, Cl, Br o I; n denota 0, 1 ó 2; m denota 1, 2 ó 3; p denota 0, 1, 2, 3 ó 4; con la condición de que, si R¹ es CH₂OH, entonces Ar¹ no sea 2,4-diclorofenilo; y sus solvatos, sales, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones. Son inhibidores de Tankirasa y se pueden emplear, inter alia, para el tratamiento de enfermedades tales como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12002215 | 2012-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090496A1 true AR090496A1 (es) | 2014-11-19 |
Family
ID=48013911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100972A AR090496A1 (es) | 2012-03-28 | 2013-03-26 | Derivados biciclicos de pirazinona |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9120805B2 (es) |
| EP (1) | EP2831077B1 (es) |
| JP (1) | JP6096879B2 (es) |
| KR (1) | KR102070567B1 (es) |
| CN (1) | CN104169284B (es) |
| AR (1) | AR090496A1 (es) |
| AU (1) | AU2013242492B2 (es) |
| CA (1) | CA2868620C (es) |
| CL (1) | CL2014002557A1 (es) |
| CO (1) | CO7111292A2 (es) |
| DK (1) | DK2831077T3 (es) |
| EA (1) | EA027416B1 (es) |
| EC (1) | ECSP14024526A (es) |
| ES (1) | ES2585044T3 (es) |
| HK (1) | HK1203961A1 (es) |
| HR (1) | HRP20160908T1 (es) |
| HU (1) | HUE030067T2 (es) |
| IL (1) | IL234713A (es) |
| MX (1) | MX351149B (es) |
| MY (1) | MY172308A (es) |
| NZ (1) | NZ630489A (es) |
| PE (1) | PE20142186A1 (es) |
| PH (1) | PH12014501829A1 (es) |
| PL (1) | PL2831077T3 (es) |
| PT (1) | PT2831077T (es) |
| RS (1) | RS54997B1 (es) |
| SG (1) | SG11201405750YA (es) |
| SI (1) | SI2831077T1 (es) |
| TW (1) | TWI576346B (es) |
| UA (1) | UA112795C2 (es) |
| WO (1) | WO2013143663A1 (es) |
| ZA (1) | ZA201407828B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6082409B2 (ja) | 2012-03-07 | 2017-02-15 | インスティチュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用 |
| NZ630489A (en) | 2012-03-28 | 2016-04-29 | Merck Patent Gmbh | Bicyclic pyrazinone derivatives |
| WO2013189905A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Pyrrolopyrazone inhibitors of tankyrase |
| JP6456392B2 (ja) | 2013-09-11 | 2019-01-23 | インスティチュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用 |
| AU2014372896B2 (en) * | 2013-12-23 | 2018-08-16 | Merck Patent Gmbh | Imidazopyrazinone derivatives |
| KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
| KR101739003B1 (ko) * | 2014-07-11 | 2017-05-23 | 에스티팜 주식회사 | 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도 |
| WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
| WO2016006974A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof |
| PT3227297T (pt) | 2014-12-05 | 2021-04-09 | Array Biopharma Inc | Pirazol[1,5-a]pirazinas, substituídas nas posições 4 e 6, como inibidores de cinases janus |
| KR20180037265A (ko) | 2015-08-17 | 2018-04-11 | 루핀 리미티드 | Parp 억제제로서의 헤테로아릴 유도체 |
| JP6505956B2 (ja) | 2016-02-24 | 2019-04-24 | ファイザー・インク | ＪＡＫ阻害剤としてのピラゾロ［１，５−ａ］ピラジン−４−イル誘導体 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US11254668B2 (en) | 2017-08-14 | 2022-02-22 | Pfizer Inc. | Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives |
| BR112020021612A2 (pt) | 2018-05-17 | 2021-01-26 | Bayer Aktiengesellschaft | derivados substituídos de di-hidropirazolo pirazina carboxamida |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| SE9702706D0 (sv) | 1997-07-11 | 1997-07-11 | Pharmacia & Upjohn Ab | Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| CA2652167A1 (en) * | 2006-05-31 | 2007-12-06 | Philip Jones | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
| EP2114948B1 (en) * | 2006-12-28 | 2014-06-25 | AbbVie Inc. | Inhibitors of poly(adp-ribose)polymerase |
| AU2008223793B2 (en) | 2007-03-08 | 2012-08-23 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| WO2009130232A1 (en) * | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| WO2009130231A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists |
| JP5579724B2 (ja) | 2008-10-17 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環 |
| WO2011089400A1 (en) | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
| CN102933584A (zh) * | 2010-04-16 | 2013-02-13 | Abbvie公司 | 激酶的吡咯并吡嗪酮抑制剂 |
| CN102229611B (zh) * | 2011-04-26 | 2012-12-12 | 山东大学 | 2,6-二芳基吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其应用 |
| NZ630489A (en) | 2012-03-28 | 2016-04-29 | Merck Patent Gmbh | Bicyclic pyrazinone derivatives |
| WO2013189905A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Pyrrolopyrazone inhibitors of tankyrase |
-
2013
- 2013-03-19 NZ NZ630489A patent/NZ630489A/en unknown
- 2013-03-19 PL PL13712685.0T patent/PL2831077T3/pl unknown
- 2013-03-19 AU AU2013242492A patent/AU2013242492B2/en active Active
- 2013-03-19 CN CN201380017205.4A patent/CN104169284B/zh active Active
- 2013-03-19 MX MX2014011420A patent/MX351149B/es active IP Right Grant
- 2013-03-19 PE PE2014001502A patent/PE20142186A1/es active IP Right Grant
- 2013-03-19 JP JP2015502129A patent/JP6096879B2/ja active Active
- 2013-03-19 ES ES13712685.0T patent/ES2585044T3/es active Active
- 2013-03-19 US US14/388,270 patent/US9120805B2/en active Active
- 2013-03-19 SG SG11201405750YA patent/SG11201405750YA/en unknown
- 2013-03-19 HU HUE13712685A patent/HUE030067T2/en unknown
- 2013-03-19 KR KR1020147029895A patent/KR102070567B1/ko active IP Right Grant
- 2013-03-19 EA EA201401062A patent/EA027416B1/ru not_active IP Right Cessation
- 2013-03-19 PT PT137126850T patent/PT2831077T/pt unknown
- 2013-03-19 SI SI201330254A patent/SI2831077T1/sl unknown
- 2013-03-19 MY MYPI2014702730A patent/MY172308A/en unknown
- 2013-03-19 RS RS20160596A patent/RS54997B1/sr unknown
- 2013-03-19 EP EP13712685.0A patent/EP2831077B1/en active Active
- 2013-03-19 DK DK13712685.0T patent/DK2831077T3/en active
- 2013-03-19 WO PCT/EP2013/000827 patent/WO2013143663A1/en active Application Filing
- 2013-03-19 CA CA2868620A patent/CA2868620C/en active Active
- 2013-03-19 UA UAA201411566A patent/UA112795C2/uk unknown
- 2013-03-26 AR ARP130100972A patent/AR090496A1/es active IP Right Grant
- 2013-03-27 TW TW102110996A patent/TWI576346B/zh active
-
2014
- 2014-08-13 PH PH12014501829A patent/PH12014501829A1/en unknown
- 2014-08-20 CO CO14182299A patent/CO7111292A2/es unknown
- 2014-09-18 IL IL234713A patent/IL234713A/en active IP Right Grant
- 2014-09-25 CL CL2014002557A patent/CL2014002557A1/es unknown
- 2014-10-27 ZA ZA2014/07828A patent/ZA201407828B/en unknown
- 2014-10-27 EC ECIEPI201424526A patent/ECSP14024526A/es unknown
-
2015
- 2015-05-19 HK HK15104737.3A patent/HK1203961A1/xx unknown
-
2016
- 2016-07-19 HR HRP20160908TT patent/HRP20160908T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090496A1 (es) | Derivados biciclicos de pirazinona | |
| AR090896A1 (es) | DERIVADOS DE PIRROLOTRIAZINONA COMO INHIBIDORES DE TANKs Y PARP-1 | |
| AR092366A1 (es) | Derivados de (aza-)isoquinolinona | |
| AR094981A1 (es) | Derivados de imidazopirimidinas | |
| AR090240A1 (es) | Derivados de triazolopirazina | |
| AR089810A1 (es) | Derivados de triazolo[4,5-d]pirimidina | |
| AR100333A1 (es) | Derivados de heterociclil-butanamida | |
| AR088925A1 (es) | Derivados de 3-cianaril-1h-pirrolo[2,3-b]piridina | |
| AR094982A1 (es) | Derivados de triazolo[4,5-d]pirimidina | |
| AR089945A1 (es) | DERIVADOS DE FURO[3,2-B] Y TIENO[3,2-B]PIRIDINA COMO MODULADORES DE TBK1 E IKKe | |
| AR087807A1 (es) | Derivados de benzonitrilo | |
| AR092670A1 (es) | Derivados de quinazolinona | |
| AR100340A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR090602A1 (es) | AMIDAS CICLICAS Y HETEROCICLOS COMO INHIBIDORES DE MetAP-2 | |
| AR077488A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de autotaxina, medicamentos que los contienen y uso de los mismos para el tratamiento y/o prevencion de cancer y enfermedades tumorales. | |
| AR093512A1 (es) | Derivados heterociclicos como moduladores de la actividad de cinasas | |
| AR093017A1 (es) | MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR097087A1 (es) | Derivados de oxoquinazolinil-butanamida | |
| AR092365A1 (es) | Derivados de piridopirimidina | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR096235A1 (es) | Arilquinazolinas | |
| AR091939A1 (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |